Metamizol Tad (Metamizole Sodium Monohydrate)

Metamizole works by inhibiting cyclooxygenase enzymes, which lowers prostaglandin production and reduces inflammation‑related pain. It also influences endogenous opioid pathways, enhancing pain‑modulating signals in the central nervous system. Together, these actions provide both analgesic and antipyretic effects.

The exact dose of Metamizol Tad is determined by the prescribing clinician based on the patient’s condition, age, weight, and response to therapy. Dosing is individualized and administered by a healthcare professional via intramuscular or intravenous injection.

Safety data for Metamizole in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and only under close medical supervision.

To place an order, submit an enquiry on the Metamizol Tad product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Metamizole offers rapid analgesic and antipyretic effects similar to non‑steroidal anti‑inflammatory drugs (NSAIDs) but is often chosen when NSAIDs are contraindicated or when a stronger pain relief is required. Unlike opioids, it does not act on µ‑receptors, reducing the risk of typical opioid‑related side effects, though it carries a unique risk of agranulocytosis.

Store Metamizol Tad at ambient temperature, preferably below 25 °C. Keep the vials in their original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly sealed when not in use.

Metamizol Tad is supplied as a sterile injectable solution and must be administered by a qualified healthcare professional. It can be given either intramuscularly or intravenously, depending on the clinical situation and the prescriber’s recommendation.

The most serious adverse events include agranulocytosis, which can lead to severe infections, and life‑threatening allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome. Immediate medical attention is required if patients develop signs of infection, unexplained fever, skin rash, or breathing difficulties.

Metamizol Tad should be avoided in individuals with known hypersensitivity to Metamizole or other pyrazolones, in patients with severe hepatic impairment, and in those who have previously experienced agranulocytosis. Caution is also advised for patients with uncontrolled hypertension or active bleeding disorders.